|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US5091513A
(en)
|
1987-05-21 |
1992-02-25 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
|
US5525491A
(en)
|
1991-02-27 |
1996-06-11 |
Creative Biomolecules, Inc. |
Serine-rich peptide linkers
|
|
WO1994012520A1
(en)
|
1992-11-20 |
1994-06-09 |
Enzon, Inc. |
Linker for linked fusion polypeptides
|
|
US5965542A
(en)
|
1997-03-18 |
1999-10-12 |
Inex Pharmaceuticals Corp. |
Use of temperature to control the size of cationic liposome/plasmid DNA complexes
|
|
JP2002502831A
(ja)
|
1998-02-03 |
2002-01-29 |
イネックス ファーマシューティカルズ コーポレイション |
癌の治療に用いる血清に対して安定なプラスミド脂質粒子の全身供与
|
|
US6410328B1
(en)
|
1998-02-03 |
2002-06-25 |
Protiva Biotherapeutics Inc. |
Sensitizing cells to compounds using lipid-mediated gene and compound delivery
|
|
US6211140B1
(en)
|
1999-07-26 |
2001-04-03 |
The Procter & Gamble Company |
Cationic charge boosting systems
|
|
EP1390490B1
(en)
|
2001-05-24 |
2009-04-15 |
Genzyme Corporation |
Muscle-specific expression vectors
|
|
ATE291925T1
(de)
|
2001-06-05 |
2005-04-15 |
Curevac Gmbh |
Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie
|
|
DE10162480A1
(de)
|
2001-12-19 |
2003-08-07 |
Ingmar Hoerr |
Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
|
|
EP1519714B1
(en)
|
2002-06-28 |
2010-10-20 |
Protiva Biotherapeutics Inc. |
Method and apparatus for producing liposomes
|
|
DE10229872A1
(de)
|
2002-07-03 |
2004-01-29 |
Curevac Gmbh |
Immunstimulation durch chemisch modifizierte RNA
|
|
AU2004257373B2
(en)
|
2003-07-16 |
2011-03-24 |
Arbutus Biopharma Corporation |
Lipid encapsulated interfering RNA
|
|
US6927663B2
(en)
|
2003-07-23 |
2005-08-09 |
Cardiac Pacemakers, Inc. |
Flyback transformer wire attach method to printed circuit board
|
|
DE10335833A1
(de)
|
2003-08-05 |
2005-03-03 |
Curevac Gmbh |
Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
|
|
CN1882693B
(zh)
|
2003-09-15 |
2012-08-15 |
普洛体维生物治疗公司 |
聚乙二醇修饰的脂质化合物及其应用
|
|
CA2569664C
(en)
|
2004-06-07 |
2013-07-16 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering rna
|
|
US7745651B2
(en)
|
2004-06-07 |
2010-06-29 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use
|
|
DE102004042546A1
(de)
|
2004-09-02 |
2006-03-09 |
Curevac Gmbh |
Kombinationstherapie zur Immunstimulation
|
|
DE102005023170A1
(de)
|
2005-05-19 |
2006-11-23 |
Curevac Gmbh |
Optimierte Formulierung für mRNA
|
|
JP5639338B2
(ja)
|
2005-07-27 |
2014-12-10 |
プロチバ バイオセラピューティクス インコーポレイティッド |
リポソームの製造システムおよび製造方法
|
|
DE102006007433A1
(de)
|
2006-02-17 |
2007-08-23 |
Curevac Gmbh |
Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure
|
|
JP2010507361A
(ja)
|
2006-07-31 |
2010-03-11 |
キュアバック ゲーエムベーハー |
具体的には免疫刺激剤／アジュバントとしての、一般式（Ｉ）：ＧｌＸｍＧｎ、または一般式（ＩＩ）：ＣｌＸｍＣｎで表される核酸
|
|
CA3144493A1
(en)
|
2006-10-03 |
2008-04-10 |
Arbutus Biopharma Corporation |
Lipid containing formulations
|
|
WO2008052322A1
(en)
|
2006-10-30 |
2008-05-08 |
Viventia Biotech Inc. |
Immunotoxγn fusions comprising an antibody fragment and a plant toxin linked by protease cleavable linkers
|
|
DE102006051516A1
(de)
|
2006-10-31 |
2008-05-08 |
Curevac Gmbh |
(Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
|
|
DE102006061015A1
(de)
|
2006-12-22 |
2008-06-26 |
Curevac Gmbh |
Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
|
|
DE102007001370A1
(de)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
|
WO2008103276A2
(en)
|
2007-02-16 |
2008-08-28 |
Merck & Co., Inc. |
Compositions and methods for potentiated activity of biologicaly active molecules
|
|
WO2009030254A1
(en)
|
2007-09-04 |
2009-03-12 |
Curevac Gmbh |
Complexes of rna and cationic peptides for transfection and for immunostimulation
|
|
EP3100718B1
(en)
|
2008-01-02 |
2019-11-27 |
Arbutus Biopharma Corporation |
Improved compositions and methods for the delivery of nucleic acids
|
|
JP5721441B2
(ja)
|
2008-01-31 |
2015-05-20 |
キュアバック ゲーエムベーハーＣｕｒｅｖａｃ Ｇｍｂｈ |
免疫賦活剤／アジュバントとしての式（Ｉ）（ＮｕＧｌＸｍＧｎＮｖ）ａで表される核酸分子及びその誘導体
|
|
EP2279254B1
(en)
|
2008-04-15 |
2017-07-05 |
Protiva Biotherapeutics Inc. |
Novel lipid formulations for nucleic acid delivery
|
|
WO2009127230A1
(en)
|
2008-04-16 |
2009-10-22 |
Curevac Gmbh |
MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
|
|
WO2010037408A1
(en)
|
2008-09-30 |
2010-04-08 |
Curevac Gmbh |
Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
|
|
EP3699172A3
(en)
|
2008-11-10 |
2020-11-18 |
Arbutus Biopharma Corporation |
Novel lipids and compositions for the delivery of therapeutics
|
|
WO2010088927A1
(en)
|
2009-02-09 |
2010-08-12 |
Curevac Gmbh |
Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds
|
|
US8399625B1
(en)
|
2009-06-25 |
2013-03-19 |
ESBATech, an Alcon Biomedical Research Unit, LLC |
Acceptor framework for CDR grafting
|
|
US8569256B2
(en)
|
2009-07-01 |
2013-10-29 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
|
ES2613498T3
(es)
|
2009-07-01 |
2017-05-24 |
Protiva Biotherapeutics Inc. |
Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
|
|
FR2948364B1
(fr)
|
2009-07-21 |
2011-07-15 |
Rhodia Operations |
Procede de preparation d'un fluorure d'halogenoacetyle et de ses derives
|
|
US20110053829A1
(en)
|
2009-09-03 |
2011-03-03 |
Curevac Gmbh |
Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
|
|
WO2011066651A1
(en)
|
2009-12-01 |
2011-06-09 |
Protiva Biotherapeutics, Inc. |
Snalp formulations containing antioxidants
|
|
CA3044884A1
(en)
|
2009-12-07 |
2011-06-16 |
Arbutus Biopharma Corporation |
Compositions for nucleic acid delivery
|
|
WO2011069529A1
(en)
|
2009-12-09 |
2011-06-16 |
Curevac Gmbh |
Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
|
|
US20130017223A1
(en)
|
2009-12-18 |
2013-01-17 |
The University Of British Columbia |
Methods and compositions for delivery of nucleic acids
|
|
US20130116419A1
(en)
|
2010-01-22 |
2013-05-09 |
Daniel Zewge |
Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry
|
|
EP3391877A1
(en)
|
2010-04-08 |
2018-10-24 |
The Trustees of Princeton University |
Preparation of lipid nanoparticles
|
|
KR101773643B1
(ko)
|
2010-04-28 |
2017-08-31 |
교와 핫꼬 기린 가부시키가이샤 |
양이온성 지질
|
|
US20130123338A1
(en)
|
2010-05-12 |
2013-05-16 |
Protiva Biotherapeutics, Inc. |
Novel cationic lipids and methods of use thereof
|
|
EP2387999A1
(en)
|
2010-05-21 |
2011-11-23 |
CureVac GmbH |
Histidine-containing solution for transfection and/or injection of nucleic acids and uses thereof
|
|
EP4481047A3
(en)
|
2010-06-03 |
2025-04-16 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
|
DK2593797T3
(da)
|
2010-07-16 |
2019-08-05 |
Bioatla Llc |
Hidtil ukendte fremgangsmåder til proteinevolution
|
|
WO2012016184A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
|
EP2449113B8
(en)
|
2010-07-30 |
2015-11-25 |
CureVac AG |
Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
|
|
WO2012019630A1
(en)
|
2010-08-13 |
2012-02-16 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
|
|
US8466122B2
(en)
|
2010-09-17 |
2013-06-18 |
Protiva Biotherapeutics, Inc. |
Trialkyl cationic lipids and methods of use thereof
|
|
WO2012089225A1
(en)
|
2010-12-29 |
2012-07-05 |
Curevac Gmbh |
Combination of vaccination and inhibition of mhc class i restricted antigen presentation
|
|
US9999673B2
(en)
|
2011-01-11 |
2018-06-19 |
Alnylam Pharmaceuticals, Inc. |
PEGylated lipids and their use for drug delivery
|
|
WO2012116715A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in newborns and infants
|
|
WO2012113413A1
(en)
|
2011-02-21 |
2012-08-30 |
Curevac Gmbh |
Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
|
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
|
CA2831613A1
(en)
|
2011-03-31 |
2012-10-04 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
US8691750B2
(en)
|
2011-05-17 |
2014-04-08 |
Axolabs Gmbh |
Lipids and compositions for intracellular delivery of biologically active compounds
|
|
WO2013016058A1
(en)
|
2011-07-22 |
2013-01-31 |
Merck Sharp & Dohme Corp. |
Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
|
|
JP6250543B2
(ja)
|
2011-09-27 |
2017-12-20 |
アルニラム・ファーマシューティカルズ・インコーポレーテッド |
ジ脂肪族置換ｐｅｇ化脂質
|
|
US8762704B2
(en)
|
2011-09-29 |
2014-06-24 |
Apple Inc. |
Customized content for electronic devices
|
|
JP6053688B2
(ja)
|
2011-10-07 |
2016-12-27 |
国立大学法人三重大学 |
キメラ抗原受容体
|
|
DE21212055T1
(de)
|
2011-12-07 |
2022-08-04 |
Alnylam Pharmaceuticals, Inc. |
Biologisch abbaubare lipide zur freisetzung von wirkstoffen
|
|
US20140308304A1
(en)
|
2011-12-07 |
2014-10-16 |
Alnylam Pharmaceuticals, Inc. |
Lipids for the delivery of active agents
|
|
WO2013086322A1
(en)
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
|
|
CN104159615B
(zh)
|
2011-12-12 |
2017-08-18 |
协和发酵麒麟株式会社 |
含有阳离子性脂质的组合的脂质纳米粒子
|
|
ES2923757T3
(es)
|
2011-12-16 |
2022-09-30 |
Modernatx Inc |
Composiciones de ARNm modificado
|
|
WO2013113326A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
|
|
EP2623121A1
(en)
|
2012-01-31 |
2013-08-07 |
Bayer Innovation GmbH |
Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
|
|
WO2013113325A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Negatively charged nucleic acid comprising complexes for immunostimulation
|
|
WO2013120499A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
|
|
WO2013120498A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
|
|
WO2013120500A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
|
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
|
ES2660129T3
(es)
|
2012-03-27 |
2018-03-20 |
Curevac Ag |
Moléculas de ácido nucleico artificiales que comprenden un 5'UTR-TOP
|
|
WO2013143698A1
(en)
|
2012-03-27 |
2013-10-03 |
Curevac Gmbh |
Artificial nucleic acid molecules
|
|
RU2658490C2
(ru)
|
2012-03-27 |
2018-06-21 |
Кьюрвак Аг |
Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков или пептидов
|
|
EP3553089A1
(en)
|
2012-05-10 |
2019-10-16 |
Bioatla, LLC |
Multi-specific monoclonal antibodies
|
|
EP2854857B1
(en)
|
2012-05-25 |
2018-11-28 |
CureVac AG |
Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings
|
|
US9415109B2
(en)
|
2012-07-06 |
2016-08-16 |
Alnylam Pharmaceuticals, Inc. |
Stable non-aggregating nucleic acid lipid particle formulations
|
|
SG11201506052PA
(en)
|
2013-02-22 |
2015-09-29 |
Curevac Gmbh |
Combination of vaccination and inhibition of the pd-1 pathway
|
|
CN105530959B
(zh)
|
2013-03-15 |
2021-09-17 |
纪念斯隆-凯特琳癌症中心 |
多聚化技术
|
|
EP2970485A1
(en)
|
2013-03-15 |
2016-01-20 |
Merck Patent GmbH |
Tetravalent bispecific antibodies
|
|
BR112016003361A2
(pt)
|
2013-08-21 |
2017-11-21 |
Curevac Ag |
vacina do vírus sincicial respiratório (rsv)
|
|
AU2014310935B2
(en)
|
2013-08-21 |
2019-11-21 |
CureVac SE |
Combination vaccine
|
|
AU2014310932B2
(en)
|
2013-08-21 |
2019-06-06 |
CureVac SE |
Composition and vaccine for treating lung cancer
|
|
CN105517569A
(zh)
|
2013-08-21 |
2016-04-20 |
库瑞瓦格股份公司 |
狂犬病疫苗
|
|
BR112016000889A2
(pt)
|
2013-08-21 |
2017-12-12 |
Curevac Ag |
composição e vacina para tratamento de câncer de próstata
|
|
SG10201801428RA
(en)
|
2013-08-21 |
2018-03-28 |
Curevac Ag |
Method for increasing expression of rna-encoded proteins
|
|
WO2015062738A1
(en)
|
2013-11-01 |
2015-05-07 |
Curevac Gmbh |
Modified rna with decreased immunostimulatory properties
|
|
US10059655B2
(en)
|
2013-12-19 |
2018-08-28 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
|
AU2014375402B2
(en)
|
2013-12-30 |
2020-10-01 |
CureVac SE |
Artificial nucleic acid molecules
|
|
SG11201604198YA
(en)
|
2013-12-30 |
2016-07-28 |
Curevac Ag |
Methods for rna analysis
|
|
CA2927254C
(en)
|
2013-12-30 |
2023-10-24 |
Curevac Ag |
Artificial nucleic acid molecules
|
|
CA2953341C
(en)
|
2014-06-25 |
2023-01-24 |
Acuitas Therapeutics Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
EP3303598B1
(en)
|
2015-05-26 |
2025-03-19 |
Ramot at Tel-Aviv University Ltd. |
Targeted lipid particles for systemic delivery of nucleic acid molecules to leukocytes
|
|
EP3303377B1
(en)
|
2015-06-05 |
2022-11-23 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for transient gene therapy with enhanced stability
|
|
HUE067372T2
(hu)
|
2015-06-29 |
2024-10-28 |
Acuitas Therapeutics Inc |
Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására
|
|
HRP20220156T1
(hr)
|
2015-09-17 |
2022-04-15 |
Modernatx, Inc. |
Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava
|
|
CN108368028B
(zh)
|
2015-10-28 |
2021-09-03 |
爱康泰生治疗公司 |
用于递送核酸的新型脂质和脂质纳米颗粒制剂
|
|
WO2018081480A1
(en)
|
2016-10-26 |
2018-05-03 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
US12678515B2
(en)
|
2015-12-30 |
2026-07-14 |
Acuitas Therapeutics, Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
WO2017222911A1
(en)
|
2016-06-20 |
2017-12-28 |
The Board Of Trustees Of The Leland Stanford Junior University |
Circular rnas and their use in immunomodulation
|
|
US11191849B2
(en)
|
2016-06-30 |
2021-12-07 |
Arbutus Biopharma Corporation |
Compositions and methods for delivering messenger RNA
|
|
MX2019009070A
(es)
*
|
2017-02-01 |
2019-10-30 |
Modernatx Inc |
Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion.
|
|
WO2018191719A1
(en)
*
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipid delivery of therapeutic agents to adipose tissue
|
|
WO2018225873A1
(ja)
|
2017-06-09 |
2018-12-13 |
協和発酵キリン株式会社 |
核酸含有ナノ粒子
|
|
EP3638678B1
(en)
|
2017-06-14 |
2025-12-03 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
CA3071968A1
(en)
|
2017-08-04 |
2019-02-07 |
Kyowa Kirin Co., Ltd. |
Nucleic acid-containing lipid nanoparticle
|
|
JP7355731B2
(ja)
|
2017-08-16 |
2023-10-03 |
アクイタス セラピューティクス インコーポレイテッド |
脂質ナノ粒子製剤における使用のための脂質
|
|
JP7461872B2
(ja)
|
2017-08-17 |
2024-04-04 |
アクイタス セラピューティクス インコーポレイテッド |
脂質ナノ粒子製剤における使用のための脂質
|
|
WO2019089828A1
(en)
|
2017-10-31 |
2019-05-09 |
Acuitas Therapeutics, Inc. |
Lamellar lipid nanoparticles
|
|
MX2020006150A
(es)
|
2017-12-15 |
2020-11-11 |
Flagship Pioneering Innovations Vi Llc |
Composiciones que comprenden polirribonucleotidos circulares y usos de las mismas.
|
|
CN111542338B
(zh)
|
2017-12-27 |
2024-06-18 |
武田药品工业株式会社 |
含核酸脂质纳米粒子及其用途
|
|
US20190314291A1
(en)
|
2018-01-30 |
2019-10-17 |
Modernatx, Inc. |
Compositions and methods for delivery of agents to immune cells
|
|
EP3802507A1
(en)
|
2018-05-30 |
2021-04-14 |
Translate Bio, Inc. |
Vitamin cationic lipids
|
|
GB2596224B
(en)
|
2018-06-19 |
2022-09-07 |
Univ Texas |
Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
|
|
GB2575506A
(en)
|
2018-07-13 |
2020-01-15 |
Robert Pearson Stephen |
User interface device
|
|
EP3853202A1
(en)
*
|
2018-09-19 |
2021-07-28 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
MX2021003726A
(es)
|
2018-10-01 |
2021-05-13 |
BioNTech SE |
Particulas de arn que comprenden polisarcosina.
|
|
MX2021003455A
(es)
*
|
2018-10-02 |
2021-09-21 |
Intellia Therapeutics Inc |
Lípidos con amina ionizables.
|
|
WO2020219876A1
(en)
|
2019-04-25 |
2020-10-29 |
Intellia Therapeutics, Inc. |
Ionizable amine lipids and lipid nanoparticles
|
|
JP7686574B2
(ja)
|
2019-05-22 |
2025-06-02 |
マサチューセッツ インスティテュート オブ テクノロジー |
環状ｒｎａ組成物及び方法
|
|
KR102928289B1
(ko)
|
2019-06-29 |
2026-02-20 |
글로벌 라이프 사이언시즈 솔루션즈 캐나다 유엘씨 |
핵산 전달을 위한 이온화 가능한 지질
|
|
JP7600208B2
(ja)
|
2019-07-29 |
2024-12-16 |
ジョージア テック リサーチ コーポレイション |
拘束された脂質を含むナノ材料およびその使用
|
|
EP4031524A1
(en)
*
|
2019-09-19 |
2022-07-27 |
ModernaTX, Inc. |
Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
|
|
US20220378700A1
(en)
|
2019-10-18 |
2022-12-01 |
The Trustees Of The University Of Pennsylvania |
Lipid Nanoparticles and Formulations Thereof for CAR mRNA Delivery
|
|
MX2022006854A
(es)
|
2019-12-04 |
2022-11-30 |
Orna Therapeutics Inc |
Composiciones y metodos de arn circular.
|
|
WO2021204179A1
(en)
|
2020-04-09 |
2021-10-14 |
Suzhou Abogen Biosciences Co., Ltd. |
Nucleic acid vaccines for coronavirus
|
|
AU2021269137A1
(en)
|
2020-05-08 |
2022-12-15 |
Orna Therapeutics, Inc. |
Circular RNA compositions and methods
|
|
JP2024508347A
(ja)
*
|
2020-12-21 |
2024-02-27 |
ビーム セラピューティクス インク． |
エステル結合アセタールを含むナノ材料
|
|
WO2022251665A1
(en)
*
|
2021-05-28 |
2022-12-01 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles and methods of use thereof
|
|
WO2023081526A1
(en)
*
|
2021-11-08 |
2023-05-11 |
Orna Therapeutics, Inc. |
Lipid nanoparticle compositions for delivering circular polynucleotides
|